Skip to content
Markets News
Global1 min read

EU Clears Novo’s FREHEMGO for Haemophilia A Prevention

Makkler Newsroom
November 14, 2026 · Based on reporting by GlobeNewswire
Photo: Ragesoss / Wikimedia Commons · CC BY-SA 4.0

The treatment is approved for adults and children, with monthly, two-weekly or weekly dosing options using a pre-filled pen.

Key takeaways

  • The European Commission authorized FREHEMGO for haemophilia A in adults and children.
  • The treatment offers monthly, every-two-weeks or weekly dosing.
  • Novo plans to launch the drug in its first European countries in the year ahead.

The European Commission has authorized Novo’s FREHEMGO for routine prevention of bleeding episodes in adults and children with haemophilia A, with or without inhibitors. The drug can be given monthly, every two weeks or weekly using a single-use pre-filled pen.

The authorization follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in September. Novo said approval was based on results from its FRONTIER clinical trial programme.

Novo plans to launch FREHEMGO in the first European countries in the year ahead. The treatment has also been approved in Saudi Arabia and is under review by the US Food and Drug Administration and other regulators.

Topics
NVOFREHEMGO
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.